Introduction: Vedolizumab is a novel agent used to treat moderate to severe active Ulcerative Colitis (UC) and Crohn's Disease (CD). Reactive arthritis is not among the known adverse drug reactions associated with vedolizumab. Here we present a case of vedolizumab-induced reactive arthritis. Case: A 28 year-old female who had begun vedolizumab infusions for UC was admitted to the hospital with a fever (100.4°F/38°C), tachycardia (115 bpm), elevated inflammatory serum biomarkers (Table 1) and a swollen and painful left knee joint (Figure 1) presumed to be septic arthritis. She began empiric intravenous antibiotics but had no clinical response after 48 hours of therapy. Joint aspirate was negative for crystals and organisms (Table 1). Her urine and cervical STD panel was negative and IBD activity was at baseline. Additional history revealed that this was the patient's third episode of knee pain since starting her vedolizumab infusions. Her first infusion, 4 months prior, was followed by two days of mild left knee pain, which self-resolved. Her second infusion, two months after the first, was followed by 3 days of even worse but self-resolving left knee pain and swelling. She had not mentioned these episodes to her physician as they had resolved by the time of follow up.Figure 1Table 1: Lab investigationsGiven the non-response to antibiotics and the temporal relation between joint swelling and vedolizumab infusions, vedolizumab-induced reactive arthritis was suspected. She was switched from antibiotics to prednisone, with which her pain and swelling improved. Subsequent intra-articular triamcinolone injection brought full symptom resolution, further supporting the diagnosis. Discussion: Here, drug-induced reactive arthritis was diagnosed by excluding septic, crystal and IBD arthropathy and noting the temporal relation between drug infusions and symptom onset. Reactive arthritis has not been reported as an adverse reaction to vedolizumab. We recommend drug-induced reactive arthritis be considered in the differential diagnosis for any patient treated with vedolizumab who presents with mono-articular arthritis, and that patients treated with vedolizumab be questioned about joint swelling, even if self-limited. Further research is needed to elucidate the pathogenesis of this arthropathy, and refine management recommendations.